2. Academic Validation
  3. Chimeric antigen receptor therapy meets mRNA technology

Chimeric antigen receptor therapy meets mRNA technology

  • Trends Biotechnol. 2024 Feb;42(2):228-240. doi: 10.1016/j.tibtech.2023.08.005.
Jiacai Wu 1,  Weigang Wu 2,  Boping Zhou 3,  Bin Li 4
Affiliations

Affiliations

  • 1 Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China; School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
  • 2 Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China.
  • 3 Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China; School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China. Electronic address: zhoubp@hotmail.com.
  • 4 Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China; School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China. Electronic address: libin@mail.sustech.edu.cn.
PMID: 37741706 DOI: 10.1016/j.tibtech.2023.08.005
Abstract

Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have emerged as a new game changer in Cancer Immunotherapy. The utility of CAR T cell therapy against hematological malignancies has been validated in clinical practice. Other CAR immune cells are currently under investigation to improve the potency of CAR therapy in solid tumors. As a new class of therapeutic modalities, mRNA-based therapeutics hold enormous potential beyond COVID-19 mRNA vaccines. Arming immune cells with mRNA-encoded CARs represents a new frontier in Cancer and beyond, enabling in vivo generation of CAR cells without causing transgene integration. In this review, we summarize recent advances in mRNA-based CAR immunotherapies and highlight their opportunities and challenges for the development of a new generation of living drugs.

Keywords

chimeric antigen receptor; delivery system; immune cell; immunotherapy; mRNA.

Figures
Products